Harvard Bioscience (HBIO) Scheduled to Post Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIOGet Free Report) is scheduled to release its earnings data on Tuesday, April 23rd.

Harvard Bioscience (NASDAQ:HBIOGet Free Report) last posted its quarterly earnings data on Thursday, March 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Harvard Bioscience had a positive return on equity of 2.75% and a negative net margin of 3.04%. The business had revenue of $28.15 million during the quarter, compared to the consensus estimate of $27.80 million.

Harvard Bioscience Stock Down 6.8 %

HBIO stock opened at $3.70 on Monday. Harvard Bioscience has a twelve month low of $3.69 and a twelve month high of $6.29. The company has a market cap of $160.58 million, a PE ratio of -46.24 and a beta of 1.42. The business’s 50-day simple moving average is $4.32 and its 200 day simple moving average is $4.50. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.42.

Institutional Investors Weigh In On Harvard Bioscience

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA grew its position in Harvard Bioscience by 47.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 3,200 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Harvard Bioscience during the second quarter worth about $37,000. Public Employees Retirement System of Ohio acquired a new stake in Harvard Bioscience during the third quarter worth about $40,000. Barclays PLC acquired a new stake in Harvard Bioscience during the second quarter worth about $43,000. Finally, Lazard Asset Management LLC grew its position in Harvard Bioscience by 230.5% during the first quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 4,966 shares in the last quarter. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Company Profile

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

See Also

Earnings History for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.